The FDA has granted accelerated approval to Otsuka’s sibeprenlimab (Voyxact) for proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. The monoclonal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback